Company: Healx Ltd.
Headquarters: Cambridge, United Kingdom
Founded: 2014
Funding: $47 million (Series B, 2022)
Ownership: Private
Healx is an AI-powered drug discovery company specializing in rare and neurological diseases. The company combines artificial intelligence with deep pharmacological expertise to identify new therapeutic uses for existing drugs (drug repurposing) and to advance novel treatments for rare diseases. Healx's mission is to accelerate the development of treatments for the 300 million people worldwide living with rare diseases[1].
The company has established a particular focus on neurological and neurodegenerative conditions, including [Parkinson's disease, [Alzheimer's disease, and rare neurological disorders. Their AI platform, Healnet, analyzes massive datasets to identify disease-treatment connections that would be difficult or impossible for humans to discover through traditional research methods.
Healnet is Healx's proprietary AI platform that integrates multiple data sources and machine learning models:
Data Sources:
AI Capabilities:
Healx specializes in drug repurposing (also called drug repositioning) - finding new uses for existing drugs:
Advantages:
Healx has established a significant pipeline of programs targeting neurological conditions:
| Program | Approach | Stage | Partner |
|---|---|---|---|
| HL-001 | Drug repurposing | Preclinical | Founded by The Michael J. Fox Foundation |
| GBA-PD program | Genetic targeting | Discovery | Parkinson's disease UK |
Healx's lead Parkinson's disease program leverages their AI platform to identify existing drugs that could be repurposed:
| Program | Approach | Stage |
|---|---|---|
| HL-003 | Multi-target approach | Discovery |
| Combination therapy program | Drug combinations | Discovery |
Healx has programs in several rare neurological conditions:
Healx operates through a combination of internal programs and partnerships:
Academic Partnerships:
Patient Advocacy Partnerships:
Pharmaceutical Partnerships:
| Year | Round | Amount | Investors |
|---|---|---|---|
| 2022 | Series B | $47M | Accel, Better Ventures, b10 |
| 2020 | Series A | $14M | Angel CoFund, Jonathan Milner |
| 2018 | Seed | $3.5M | Various angels |
Healx's mission is to bring treatments to patients faster:
The company has made neurological diseases a strategic priority: